NEUROCRINE BIOSCIENCES INC

NBIX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $13.3B · 2,000 employees
154
SEC Filings
$161
Close 2026-06-01
2,000
Employees

Business Summary

PARTI Overview Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated wit...

Latest Stock Quote

NBIX 2026-06-01 $161 O:$159.36 H:$161.8 L:$157.44 Vol:1.2M VWAP:$160.3996
origin leaf: 5ddc873be3b55c6d9cf71f8940571ada9bf2dc26be5bdcdcf14a46667e63beed

Next Earnings

Q2 FY2026 — expected 2026-07-28

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-112025-12-310000914475-26-000007EDGAR65K words
2025-02-102024-12-310000914475-25-000037EDGAR—
2024-02-092023-12-310000914475-24-000054EDGAR—
2023-02-092022-12-310000914475-23-000011EDGAR—
2022-02-112021-12-310000914475-22-000013EDGAR—
2021-02-052020-12-310000914475-21-000020EDGAR—
2020-02-072019-12-310001564590-20-003773EDGAR—
2019-02-082018-12-310001564590-19-002328EDGAR—
2018-02-132017-12-310001193125-18-042794EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-10-282025-09-300000914475-25-000181EDGAR38K words
2025-07-302025-06-300000914475-25-000158EDGAR—
2025-05-052025-03-310000914475-25-000100EDGAR—
2024-10-302024-09-300000914475-24-000211EDGAR—
2024-08-012024-06-300000914475-24-000181EDGAR—
2024-05-012024-03-310000914475-24-000117EDGAR—
2023-10-312023-09-300000914475-23-000073EDGAR—
2023-08-012023-06-300000914475-23-000057EDGAR—
2023-05-032023-03-310000914475-23-000044EDGAR—
2022-11-012022-09-300000914475-22-000058EDGAR—
2022-08-042022-06-300000914475-22-000044EDGAR—
2022-05-042022-03-310000914475-22-000022EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-060001193125-26-142904EDGAR67K words
2026-02-110000914475-26-000006EDGAR—
2025-11-240000914475-25-000186EDGAR—
2025-10-280000914475-25-000180EDGAR—
2025-07-300000914475-25-000157EDGAR—
2025-05-300000914475-25-000139EDGAR—
2025-05-220000914475-25-000120EDGAR—
2025-05-050000914475-25-000099EDGAR—
2025-04-040000914475-25-000081EDGAR—
2025-02-060000914475-25-000034EDGAR—

154 total filings indexed. 123 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0000914475
TickerNBIX
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.neurocrine.com
Listed1996-05-23

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: efca31c9ea3f30c3f45df57075ca6f2922b4c328e957e5e91735d90447d27c33
parent: 1935153f74f717659c5e74e894ec0753bd7084cbac5fd8407dc4922f750a9be6
content hash: ae45cd00c07d5f9b88c2a7140b900946cd9a9392ae6eca2c8d9a4ca8f08051cf
signed: 2026-06-02T19:01:59.725Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf